While the gene therapy field has suffered a series of setbacks of late, with a number of trials being paused due to safety concerns and investors being spooked, the fundamentals of the sector remain in good shape.
Purespring Positive About Prospects Despite Burst Biotech Bubble
UK Gene Therapy Moving Quickly Towards Clinic
Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.
